// App-Quantinova.ai

LB-094 : Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma

Researchers

Presenter

  • Luigi Buonaguro

Principal Investigators

  • Markus Loeffler

  • Sarah Missel

  • Roberto Accolla

  • Yuk Ting Ma

  • Tanguy Chaumette

  • Regina Heidenreich

  • Alfred Knigsrainer

  • Joerg Ludwig

  • Diego Alcoba

  • Heiko Schuster

  • Cecile Gouttenfangeas

  • Greta Forlani

  • Maria Tagliamonte

  • Paolo A. Ascierto

  • Antonio Avallone

  • Marco Borrelli

  • Hans-Georg Rammensee

  • Bruno Sangro

  • Mercedes Iarrairaegui

  • Sven Francque

  • Luisa Vonghia

  • Stefania Gori

  • Tony Weinschenk

  • Carsten Reinhardt

  • Ulrike Gnad-Vogt

  • Harpreet Singh

Medical Centers

  • ISTITUTO NAZIONALE TUMORI IRCCS - Fondazione Pascale, NAPLES, Italy

  • Immatics Biotechnologies GmbH, Tubingen, Germany

  • Eberhard Karls University, Tubingen, Germany

  • University of Insubria, Department of Medicine and Surgery, Varese, Italy

  • University of Birmingham, Birmingham, United Kingdom

  • Universitary Hospital of Nantes, NANTES, France

  • Curevac GMBH, Tuebingen, Germany

  • Clinica Universidad of Navarra, PAMPLONA, Spain

  • University Hospital Antwerp, ANTWERP, Netherlands

  • Ospedale Sacro Cuore - Don G. Calabria, NEGRAR, Italy

  • Immatics Biotechnologies GmbH, Tubingen, Germany

Locations

  • Italy

  • Germany

  • United Kingdom

  • France

  • Spain

  • Netherlands

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • Human Leukocyte Antigen – DR isotype

  • Major Histocompatibility Complex, Class I, A

  • T helper 2

  • Type 1 T helper

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT03203005

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved